ArticleCancer2012
Costs and trends in pancreatic cancer treatment.
Article in Cancer, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04984174 (Survival Rate and Treatment Cost in Patients With Pancreatic Cancer With the Advent of New Chemotherapeutic Agents in Korea), which is not on this map. Cited by 54 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Survival Rate and Treatment Cost in Patients With Pancreatic Cancer With the Advent of New Chemotherapeutic Agents in Korea: An Analysis Using NHIS Database and K-PaC Registry Focusing on the Newest One, Liposomal Irinotecan
Who cites it
54 citing papers in PubMed, 2 syntheses or guidelines pooled it, 93 citations in OpenAlex.
- Comparison of Outcomes of Enucleation vs. Standard Surgical Resection for Pancreatic Neoplasms: A Systematic Review and Meta-Analysis.Frontiers in surgery · 2021Pooled it
- A Systematic Review of the Burden of Pancreatic Cancer in Europe: Real-World Impact on Survival, Quality of Life and Costs.Journal of gastrointestinal cancer · 2015Pooled it
- Cost-effectiveness analysis of FOLFIRINOX vs gemcitabine with nab-paclitaxel as adjuvant treatment for resected pancreatic cancer in the United States based on PRODIGE-24 and APACT trials.Journal of managed care & specialty pharmacy · 2021Trial
- Real-World Assessment of Health Care Costs for Patients with Metastatic Pancreatic Cancer Following Initiation of First-Line Chemotherapy.Journal of managed care & specialty pharmacy · 2020Trial
- Gastrojejunostomy in patients with unresectable pancreatic head cancer - the use of Roux loop significantly shortens the hospital length of stay.World journal of gastroenterology · 2013Trial
- Healthcare resource utilization and economic burden of metastatic pancreatic cancer: a US commercial and Medicare claims analysis.Future oncology (London, England) · 2026Article
- Examining health system stakeholder-reported barriers and solutions to foregut cancer care.American journal of surgery · 2026Article
- Facilitators to oncological care in foregut cancer: The patient perspective.Surgical oncology insight · 2025Article
- Impact of Financial Toxicity on Treatment Adherence and Quality of Life in Pancreatic Cancer.JCO oncology practice · 2025Article
- Exploring the Costs of Hospital and Emergency Department Utilisation in the First Three Years After Diagnosis for Adults Diagnosed With Pancreatic Cancer in Queensland, Australia.Cancer medicine · 2025Article
- Identification of key hub genes in pancreatic ductal adenocarcinoma: an integrative bioinformatics study.Frontiers in bioinformatics · 2025Article
- Economic evaluation of NALIRIFOX vs. nab-paclitaxel and gemcitabine regimens for first-line treatment of metastatic pancreatic ductal adenocarcinoma from U.S. perspective.Cost effectiveness and resource allocation : C/E · 2024Article
- Cost trends of metastatic renal cell carcinoma therapy: the impact of oral anticancer agents and immunotherapy.JNCI cancer spectrum · 2024Article
- Quality of Life in Patients with Pancreatic Cancer-A Literature Review.International journal of environmental research and public health · 2023Review
- Pancreatic Cancer in Iran - Result of the Iranian National Cancer Registry Program.Asian Pacific journal of cancer prevention : APJCP · 2022Article
- Cost-effectiveness of neoadjuvant FOLFIRINOX versus gemcitabine plus nab-paclitaxel in borderline resectable/locally advanced pancreatic cancer patients.Cancer reports (Hoboken, N.J.) · 2022Article
- Cost-Effectiveness of a Risk-Tailored Pancreatic Cancer Early Detection Strategy Among Patients With New-Onset Diabetes.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2022Article
- Trends and Projections in National United States Health Care Spending for Gastrointestinal Malignancies (1996-2030).Gastroenterology · 2022Article
- Is Improved Survival in Early-Stage Pancreatic Cancer Worth the Extra Cost at High-Volume Centers?Journal of the American College of Surgeons · 2021Article
- Communicating Value: Use of a Novel Framework in the Assessment of an Enhanced Recovery Initiative.Annals of surgery · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
backgroundPancreatic cancer poses a substantial morbidity and mortality burden in the United States, and predominantly affects older adults. The objective of this study was to estimate the direct medical costs of pancreatic cancer treatment in a population-based cohort of Medicare beneficiaries, and the contribution of different treatment modalities and health care services to the total cost of care and trends in costs over time.
methodsIn the linked Surveillance, Epidemiology, and End Results (SEER)-Medicare database, pancreatic cancer patients were identified who were aged 66 years or older and who were diagnosed from 2000 to 2007. Total direct medical costs were estimated from Medicare payments overall and within categories of care. Costs attributable to pancreatic cancer were estimated by subtracting the costs of medical care in a matched cohort of cancer-free beneficiaries.
resultsA total of 15,037 patients were identified, of whom 97% were observed from diagnosis until death. Mean total direct medical costs were $65,500. Mean total costs were greater for patients with resectable locoregional disease ($134,700) than for those with unresectable locoregional or distant disease ($65,300 and $49,000, respectively). Hospitalizations and cancer-directed procedures collectively accounted for the largest fraction of health care costs. The total cost of care appeared to increase slightly over the study period (P = .05). The mean costs attributable to pancreatic cancer were $61,700.
conclusionsDespite poor prognosis and short survival, the economic burden of pancreatic cancer in the elderly is substantial. Demographic trends, greater use of targeted therapies, and possible implementation of screening strategies are likely to impact treatment patterns and costs in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.